<?xml version="1.0" encoding="UTF-8"?>
<p>TTO has also demonstrated a potent anti-biofilm activity against MRSA biofilms with pooled MIC and MBC data of 0.125–2% and 1–8% (
 <italic>v</italic>/
 <italic>v</italic>), respectively [
 <xref rid="B97-antibiotics-09-00909" ref-type="bibr">97</xref>,
 <xref rid="B98-antibiotics-09-00909" ref-type="bibr">98</xref>]. It also completely eradicated MRSA biofilm cultured from an infected cochlear implant within an hour in one in vitro study [
 <xref rid="B99-antibiotics-09-00909" ref-type="bibr">99</xref>], and was as effective as vancomycin in eradicating MRSA biofilm on tympanostomy tube in another in vitro study [
 <xref rid="B100-antibiotics-09-00909" ref-type="bibr">100</xref>]. Biofilms are a complex and organized bacterial communities that are embedded in a self-produced polymeric matrix, which could prevent the antibiotics from entering and become in contact with the bacteria [
 <xref rid="B101-antibiotics-09-00909" ref-type="bibr">101</xref>]. These bacteria within biofilms may be 100–1000 times less susceptible than their free-living counter-parts [
 <xref rid="B101-antibiotics-09-00909" ref-type="bibr">101</xref>]. Additional to its antibacterial effects, TTO is effective at low concentration as an anti-inflammatory agent (≤0.125%) that could offer additional benefits when it is used for treatment of skin infections [
 <xref rid="B87-antibiotics-09-00909" ref-type="bibr">87</xref>].
</p>
